Keith C. Hayes
Professor
 |
PH.D. University of Massachusetts |
Postgraduate training in neurophysiology and biomechanics provided the grounding for my interest in processes of motor control. This interest was reflected in my research into various aspects of human reflex physiology and balance. More recently my research activities have turned to clinical applications of electrophysiology particularly with regard to spasticity and spinal cord injuries. Our current research activity involves use of transcortical magnetic stimulation of motor cortex to identify spared corticospinal influence in spinal cord injured patients. We are also undertaking clinical trials of 4-Aminopyridine, a potassium channel blocking agent, potentially capable of reversing conduction block due to demyelination in neurons of the spinal cord.
Davies AL, Hayes KC, Shi R. Recombinant human TNFalpha induces concentration-dependent and reversible alterations in the electrophysiological properties of axons in Mammalian spinal cord. J Neurotrauma. 2006 Aug;23(8):1261-73. Hayes KC. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 2004 Winter;10(4):295-316. Review. Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil. 2004 Jan;85(1):29-34. Hayes KC, Potter PJ, Hansebout RR, Bugaresti JM, Hsieh JT, Nicosia S, Katz MA, Blight AR, Cohen R. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Clin Neuropharmacol. 2003 Jul-Aug;26(4):185-92. Hayes KC, Katz MA, Devane JG, Hsieh JT, Wolfe DL, Potter PJ, Blight AR. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol. 2003 Apr;43(4):379-85.
